Kevin Kalinsky, MD, MS, of Winship Cancer Institute of Emory University recently presented clinical trial findings that found that non-Hispanic Black (Black) women with Hormone Receptor positive/HER2-negative breast cancer, with 1-3 involved lymph nodes and recurrence scores below 25, have worse outcomes than non-Hispanic white women with similar diagnosis. Even though HR+/HER2 breast cancer if diagnosed early, is one the most survivable.
“These data demonstrate that there is a difference in outcome based on race/ethnicity in a large, randomized trial,” says Kalinsky, “Understanding why is critical, as is increasing the number of underrepresented minorities in clinical trials.”
Emory Healthcare is a foundational partner of AccessHope.
